These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

133 related articles for article (PubMed ID: 10927002)

  • 1. Central retinal artery occlusion in a patient homozygous for factor V Leiden.
    Larsson J
    Am J Ophthalmol; 2000 Jun; 129(6):816-7. PubMed ID: 10927002
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Bilateral retinal vein occlusion associated with factor V Leiden mutation.
    Spagnolo BV; Nasrallah FP
    Retina; 1998; 18(4):377-8. PubMed ID: 9730185
    [No Abstract]   [Full Text] [Related]  

  • 3. Retinal vascular occlusion and deficiencies in the protein C pathway.
    Greiner K; Hafner G; Dick B; Peetz D; Prellwitz W; Pfeiffer N
    Am J Ophthalmol; 1999 Jul; 128(1):69-74. PubMed ID: 10482096
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Influence of factor V Leiden on the development of neovascularisation secondary to central retinal vein occlusion.
    Hvarfner C; Hillarp A; Larsson J
    Br J Ophthalmol; 2003 Mar; 87(3):305-6. PubMed ID: 12598443
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Activated protein C resistance, factor V Leiden, and retinal vessel occlusion.
    Ma AD; Abrams CS
    Retina; 1998; 18(4):297-300. PubMed ID: 9730170
    [No Abstract]   [Full Text] [Related]  

  • 6. Factor V Leiden, activated protein C resistance, and retinal vein occlusion.
    Ciardella AP; Yannuzzi LA; Freund KB; DiMichele D; Nejat M; De Rosa JT; Daly JR; Sisco L
    Retina; 1998; 18(4):308-15. PubMed ID: 9730172
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Peripheral retinal neovascularization and retinal vascular occlusion associated with activated protein C resistance.
    Greven CM; Wall AB
    Am J Ophthalmol; 1997 Nov; 124(5):687-9. PubMed ID: 9372725
    [TBL] [Abstract][Full Text] [Related]  

  • 8. MTHFR C677T mutation, factor II G20210A mutation and factor V Leiden as risks factor for youth retinal vein occlusion.
    Cruciani F; Moramarco A; Curto T; Labate A; Recupero V; Conti L; Gandolfo GM; Balacco Gabrieli C
    Clin Ter; 2003; 154(5):299-303. PubMed ID: 14994919
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Protein S deficiency with homozygous factor V Leiden mutation in central retinal vein occlusion.
    Sucak GT; Aki Z; Or M
    Can J Ophthalmol; 2007 Aug; 42(4):632-3. PubMed ID: 17641719
    [No Abstract]   [Full Text] [Related]  

  • 10. Arterial vascular occlusion associated with factor V Leiden gene mutation.
    Tayyanipour R; Pulido JS; Postel EA; Lipkowitz JL; Pisciotta A; Braza E
    Retina; 1998; 18(4):376-7. PubMed ID: 9730184
    [No Abstract]   [Full Text] [Related]  

  • 11. Retinal vein occlusion and factor V Leiden and prothrombin 20210 G:A mutations.
    Aras S; Yilmaz G; Alpas I; Baltaci V; Tayanç E; Aydin P
    Eur J Ophthalmol; 2001; 11(4):351-5. PubMed ID: 11820306
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Factor V Leiden and prothrombin 20210 A mutations in patients with central and branch retinal vein occlusion.
    Kalayci D; Gürgey A; Güven D; Parlak H; Hasiripi H
    Acta Ophthalmol Scand; 1999 Dec; 77(6):622-4. PubMed ID: 10634550
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prevalence of factor V Leiden in patients with retinal vein occlusion.
    Demirci FY; Güney DB; Akarçay K; Kir N; Ozbek U; Sirma S; Unaltuna N; Ongör E
    Acta Ophthalmol Scand; 1999 Dec; 77(6):631-3. PubMed ID: 10634553
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Anticoagulant therapy after retinal vein occlusion in patients with protein S deficiency (Protein S deficiency with homozygous factor V Leiden mutation in central retinal vein occlusion. Vol. 42[4]).
    Rehak M; Krcova V; Slavik L; Müller M; Rehak J
    Can J Ophthalmol; 2007 Dec; 42(6):875; author reply 876. PubMed ID: 18059510
    [No Abstract]   [Full Text] [Related]  

  • 15. [Venous branch occlusion due to APC resistance].
    Tost F
    Ophthalmologe; 1999 Dec; 96(12):777-80. PubMed ID: 10643310
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prevalence of factor V Leiden and activated protein C resistance in central retinal vein occlusion.
    Johnson TM; El-Defrawy S; Hodge WG; Leonard BC; Kertes PJ; Taylor SAM ; Lillicrap DP
    Retina; 2001; 21(2):161-6. PubMed ID: 11321143
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Recurrent central retinal vein occlusion in a young thrombophilic patient with factor V Leiden mutation.
    Incorvaia C; Bandello F; Parmeggiani F; D'Angelo S; Costagliola C; Sebastiani A
    Eur J Ophthalmol; 2002; 12(2):131-4. PubMed ID: 12022286
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Retinal vascular occlusion and deficiencies in the protein C pathway.
    Gamel J
    Am J Ophthalmol; 2000 Jan; 129(1):112-3. PubMed ID: 10653431
    [No Abstract]   [Full Text] [Related]  

  • 19. No excess of factor V:Q506 genotype but high prevalence of anticardiolipin antibodies without antiendothelial cell antibodies in retinal vein occlusion in young patients.
    Scott JA; Arnold JJ; Currie JM; Broadfoot C; Davidson M; Kelly KF; Graham A; Kirkpatrick JN; Greaves M
    Ophthalmologica; 2001; 215(3):217-21. PubMed ID: 11340395
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Activated protein C resistance is a risk factor for central retinal vein occlusion.
    Marcucci R; Bertini L; Liotta AA; Rogolino A; Antonucci E; Ilari I; Pepe G; Prisco D
    Ann Ital Med Int; 2000; 15(3):195-8. PubMed ID: 11059059
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.